As part of the Bioconjugation team at Abzena, Juan Carlos focuses on process development, optimization, and scale-up for protein drug conjugate biotherapies. He is also involved in the planning and execution of cGMP manufacturing campaigns for antibody drug conjugates. Juan Carlos received his Ph.D. in chemical engineering from Vanderbilt University and has extensive experience in development and manufacture of diverse biotherapeutic modalities including protein drug conjugates, conjugate vaccines, and viral vector-mediated gene therapies.
.svg)
